Organon (OGN): EPS Falls 15% — Is the $14 Sun Pharma Buyout Worth It?

Organon & Co. (OGN) Q2 2026 — Organon released Q2 2026 with its 10-Q on July 31 — no press release, no call, both suspended for the pending Sun Pharma merger. Revenue $1,558M, -2% reported but -5% ex-FX, missing ~$1,566M. Adjusted EPS $0.85, down 15%, missing ~$0.90. Adjusted EBITDA $461M, a 29.6% margin vs 32.7%. The stock closed at $13.55 — exactly unchanged. It didn't move because Organon is barely a stock any more. On April 26 it agreed to be bought by Sun Pharma for $14.00 a share in cash — ~$11.75B EV, a 103% premium to the unaffected $6.91 — and holders approved on July 23 with 98.7% of votes cast; closing is expected early 2027. Underneath, it got worse: Nexplanon, the one growth asset, fell 21% in the US, and its US rod patents expire in 2027. Net debt is $7,421M, 4.17x EBITDA, so equity is only ~25% of enterprise value. Our standalone DCF says $9.35. The deal says $14.00. THE CALL: HOLD (3/5, A BOND WITH A 33% TAIL, NOT A STOCK) — base-case value ~$13.25 vs ~$13.55 today. KEY METRICS: - OUR CALL: HOLD 3/5. Fair value $13.25 (deal-adjusted) vs $13.55 — ~2% BELOW. Standalone DCF $9.35 - DCF: unlevered FCF $1.11B (adj EBITDA $1,780M less capex $160M, network-exit/restructuring $120M, cash tax $392M), -3%/yr, -2% terminal at 8.5% = EV $9.92B less $7.42B net debt / 266.7M shares = $9.35 - Ladder 7.5/8.5/9.5%: bear $1/$0/$0, base $13.30/$9.35/$6.20, bull $26.76/$21.02/$16.38 — a 15% cash-flow swing takes the equity from $21 to zero - Reverse DCF: $13.55 implies EV $11.0B = decline of only 1.4%/yr forever vs the -5% ex-FX just printed. At the unaffected $6.91 implied EV was $9.87B, within 0.5% of our $9.92B - WALL STREET: Hold, $14.00 (deal-anchored). Raw screen mean $11.33, median $12.00, range $8-$14, 2 Buy/4 Hold/3 Sell — contaminated by stale pre-deal targets. We ALIGN on rating, DIFFER on target - THE DEAL: Sun Pharma $14.00/sh all cash, ~$11.75B EV, signed Apr 26 2026, 103% premium to the unaffected $6.91. Holders approved Jul 23, 98.7% of votes cast. Close expected early 2027. Spread $0.45/3.3% = ~6.7% annualised; price implies ~90% odds of closing (we say 93%) - Revenue $1,558M, -2% reported / -5% ex-FX (FX +$42M); US $398M -4%, Int'l $1,160M -2%. H1 $3,018M, -7% ex-FX - Adj diluted EPS $0.85 (-15%) vs ~$0.90 est; GAAP $0.40 vs $0.56. Adj EBITDA $461M vs $522M, margin 29.6% vs 32.7%; adj gross margin 58.7% vs 61.7% - Franchises: Established Brands $930M (-1%, 60% of sales), Women's Health $419M (-9%), Biosimilars $195M (+13%; Hadlima $79M +58%). Nexplanon $230M -4%: US $129M -21% on delayed 5-year-label reinsertions, Int'l $101M +31%. US rod patents expire 2027 - BALANCE SHEET: debt $8,553M less cash $1,132M = net debt $7,421M = 4.17x TTM adj EBITDA $1,780M. Avg rate 4.90%, avg maturity 4.1yr, $3,486M wall in 2028. H1 FCF $253M; dividend $0.02/qtr - FY26 framework (Feb, never revised — no call): ~$6.2B revenue, ~$1.9B adj EBITDA. H1 did $3,018M / $876M, so H2 needs ~$1,024M (+17%) What to watch: Bullish: the remaining regulatory clearances landing (spread should compress toward 1%), or US Nexplanon returning to growth in Q3/Q4. Bearish: a second request or CFIUS review, a Sun Pharma financing problem, or a third straight quarter of double-digit US Nexplanon decline into the 2027 patent expiry. We'd want the arbitrage at ~$12.60. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.